cd300f trem 1 pe cat (Miltenyi Biotec)
93
Structured Review
Miltenyi Biotec
cd300f trem 1 pe cat
Cd300f Trem 1 Pe Cat, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd300f+trem+1+fitc+cat/CD300f+(IREM-1)+Antibody%2C+anti-human%2C+FITC/us12345712-316-102-110
Average 93 stars, based on 5 article reviews
Cd300f Trem 1 Pe Cat, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd300f+trem+1+fitc+cat/CD300f+(IREM-1)+Antibody%2C+anti-human%2C+FITC/us12345712-316-102-110
Average 93 stars, based on 5 article reviews
cd300f trem 1 pe cat - by Bioz Stars,
2026-09
93/100 stars
Images
Related Articles
Binding Assay:Article Title: Cancer antigen targets and uses thereof Article Snippet: .. In certain embodiments, one or more of the flowing commercially available antibodies can be used for binding to a myeloid/AML antigen: CD70-PE cat. 355104 (Biolegend); EMR2-FITC cat. 130-104-654; EMR2-APC cat. 130-104-656 (Milteny); LTB4R1-AF700 cat. FAB099N; LTB4R1-AF405 cat. FAB099V; LTB4R1-FITC cat. NB100-64832 (Novus Biologicals); LTB4R1-PE cat. FAB099P (R&D); PIEZO1-AF488 cat. NBP11-78537; CD33-APC cat. 551378 (BD Pharmingen); ENG-APC cat. NMCD10505 (Invitrogen); MYADM cat. NBP2-24494SS (Novus); ITGA5 (CD49e)-APC cat. 328011 (Biolegend); SLC19A1-APC cat. FAB8450A (R&D); ILT3-APC (LILRB4) cat. FAB24251A (R&D); CCR1-PE cat. 130-100-368 (Milteniy); ITGA4-APC cat. FAB2450A (R&D); CD49d-PE cat. 130-099-691 (Miltenyi); ICAM1-PE cat. 130-103-909 (Miltenyi); SIRPB1-PE cat. 130-105-310 (Miltenyi); CD64-APC (FCGR1A) cat. 561189 (BD); CD300f (TREM-1)-PE cat. 130-098-472; Flow Cytometry:Article Title: Cancer antigen targets and uses thereof Article Snippet: .. Furthermore, pre-leukemic stem cells model indicated an additional set of surface genes suitable for CAR therapy Materials and Methods Flow-Cytometry We used the following antibodies to define antigen expression by flow-cytometry: CD70-PE cat. 355104 (Biolegend); EMR2-FITC cat. 130-104-654; EMR2-APC cat. 130-104-656 (Milteny); LTB4R1-AF700 cat. FAB099N; LTB4R1-AF405 cat. FAB099V; LTB4R1-FITC cat. NB100-64832 (Novus Biologicals); LTB4R1-PE cat. FAB099P (R&D) PIEZO1-AF488 cat. NBP11-78537; CD33-APC cat. 551378 (BD Pharmingen); ENG-APC cat. MHCD10505 (Invitrogen); MYADM cat. NBP2-24494SS (Novus) ITGA5 (CD49e)-APC cat. 328011 (Biolegend) SLC19A1-APC cat. FAB8450A (R&D) ILT3-APC (LILRB4) cat. FAB24251A (R&D) CCR1-PE cat. 130-100-368 (Milteniy) ITGA4-APC cat. FAB2450A (R&D); CD49d-PE cat. 130-099-691 (Miltenyi) ICAM1-PE cat. 130-103-909 (Miltenyi) SIRPB1-PE cat. 130-105-310 (Miltenyi) CD64-APC (FCGR1A) cat. 561189 (BD) CD300f (IREM-1)-PE cat. 130-098-472; Expressing:Article Title: Cancer antigen targets and uses thereof Article Snippet: .. Furthermore, pre-leukemic stem cells model indicated an additional set of surface genes suitable for CAR therapy Materials and Methods Flow-Cytometry We used the following antibodies to define antigen expression by flow-cytometry: CD70-PE cat. 355104 (Biolegend); EMR2-FITC cat. 130-104-654; EMR2-APC cat. 130-104-656 (Milteny); LTB4R1-AF700 cat. FAB099N; LTB4R1-AF405 cat. FAB099V; LTB4R1-FITC cat. NB100-64832 (Novus Biologicals); LTB4R1-PE cat. FAB099P (R&D) PIEZO1-AF488 cat. NBP11-78537; CD33-APC cat. 551378 (BD Pharmingen); ENG-APC cat. MHCD10505 (Invitrogen); MYADM cat. NBP2-24494SS (Novus) ITGA5 (CD49e)-APC cat. 328011 (Biolegend) SLC19A1-APC cat. FAB8450A (R&D) ILT3-APC (LILRB4) cat. FAB24251A (R&D) CCR1-PE cat. 130-100-368 (Milteniy) ITGA4-APC cat. FAB2450A (R&D); CD49d-PE cat. 130-099-691 (Miltenyi) ICAM1-PE cat. 130-103-909 (Miltenyi) SIRPB1-PE cat. 130-105-310 (Miltenyi) CD64-APC (FCGR1A) cat. 561189 (BD) CD300f (IREM-1)-PE cat. 130-098-472; Cloning:Article Title: Cancer antigen targets and uses thereof Article Snippet: .. Furthermore, pre-leukemic stem cells model indicated an additional set of surface genes suitable for CAR therapy Materials and Methods Flow-Cytometry We used the following antibodies to define antigen expression by flow-cytometry: CD70-PE cat. 355104 (Biolegend); EMR2-FITC cat. 130-104-654; EMR2-APC cat. 130-104-656 (Milteny); LTB4R1-AF700 cat. FAB099N; LTB4R1-AF405 cat. FAB099V; LTB4R1-FITC cat. NB100-64832 (Novus Biologicals); LTB4R1-PE cat. FAB099P (R&D) PIEZO1-AF488 cat. NBP11-78537; CD33-APC cat. 551378 (BD Pharmingen); ENG-APC cat. MHCD10505 (Invitrogen); MYADM cat. NBP2-24494SS (Novus) ITGA5 (CD49e)-APC cat. 328011 (Biolegend) SLC19A1-APC cat. FAB8450A (R&D) ILT3-APC (LILRB4) cat. FAB24251A (R&D) CCR1-PE cat. 130-100-368 (Milteniy) ITGA4-APC cat. FAB2450A (R&D); CD49d-PE cat. 130-099-691 (Miltenyi) ICAM1-PE cat. 130-103-909 (Miltenyi) SIRPB1-PE cat. 130-105-310 (Miltenyi) CD64-APC (FCGR1A) cat. 561189 (BD) CD300f (IREM-1)-PE cat. 130-098-472; Clone Assay:Article Title: Cancer antigen targets and uses thereof Article Snippet: .. Furthermore, pre-leukemic stem cells model indicated an additional set of surface genes suitable for CAR therapy Materials and Methods Flow-Cytometry We used the following antibodies to define antigen expression by flow-cytometry: CD70-PE cat. 355104 (Biolegend); EMR2-FITC cat. 130-104-654; EMR2-APC cat. 130-104-656 (Milteny); LTB4R1-AF700 cat. FAB099N; LTB4R1-AF405 cat. FAB099V; LTB4R1-FITC cat. NB100-64832 (Novus Biologicals); LTB4R1-PE cat. FAB099P (R&D) PIEZO1-AF488 cat. NBP11-78537; CD33-APC cat. 551378 (BD Pharmingen); ENG-APC cat. MHCD10505 (Invitrogen); MYADM cat. NBP2-24494SS (Novus) ITGA5 (CD49e)-APC cat. 328011 (Biolegend) SLC19A1-APC cat. FAB8450A (R&D) ILT3-APC (LILRB4) cat. FAB24251A (R&D) CCR1-PE cat. 130-100-368 (Milteniy) ITGA4-APC cat. FAB2450A (R&D); CD49d-PE cat. 130-099-691 (Miltenyi) ICAM1-PE cat. 130-103-909 (Miltenyi) SIRPB1-PE cat. 130-105-310 (Miltenyi) CD64-APC (FCGR1A) cat. 561189 (BD) CD300f (IREM-1)-PE cat. 130-098-472; |